Advertisement
Australia markets open in 10 minutes

  • ALL ORDS

    7,898.90
    +37.90 (+0.48%)
     

  • AUD/USD

    0.6425
    -0.0000 (-0.01%)
     

  • ASX 200

    7,642.10
    +36.50 (+0.48%)
     

  • OIL

    82.58
    -0.15 (-0.18%)
     

  • GOLD

    2,395.20
    -2.80 (-0.12%)
     

  • Bitcoin AUD

    98,822.77
    +3,350.78 (+3.51%)
     

  • CMC Crypto 200

    1,311.32
    +425.79 (+48.06%)
     

3 Things About CRISPR Therapeutics That Smart Investors Know

Steve Ditto, The Motley Fool
·4-min read
3 Things About CRISPR Therapeutics That Smart Investors Know

Many biotech companies have been formed hoping to be first to market with CRISPR gene-editing therapies. CRISPR Therapeutics (NASDAQ: CRSP) and its development partner Vertex Pharmaceuticals (NASDAQ: VRTX) are leading the way with the CTX001 therapy for treating sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). On June 11, CRISPR Therapeutics and Vertex held a joint press conference highlighting CTX001 results, which showed that patients in a 22-person phase 1/2 clinical trial are having a "consistent and sustained response to treatment."

Continue reading